NGM Biopharmaceuticals

NGM Biopharmaceuticals is a clinical-stage biotech firm focused on discovering and developing first-in-class therapeutics through its integrated biology platform. A key achievement was a major, long-term collaboration with Merck & Co., which provided significant validation and funding, though it was restructured in 2023 to return full rights to NGM for most assets. The company's strategy centers on deeply understanding novel biological pathways, such as GDF15, to address large-market indications with high unmet need, including hyperemesis gravidarum and cancer cachexia. NGM aims to de-risk development through rigorous translational science and patient stratification.

An integrated, biology-centric discovery platform that identifies novel drug targets through human genetics and molecular biology, generating both biologics and small molecules with a focus on endocrine and metabolic pathways like GDF15 and FGF.

In hyperemesis gravidarum, NGM120 faces little direct competition in a sparse landscape, positioning it for potential first-mover advantage. In cancer cachexia, the field is challenging with past failures, but NGM's novel GDF15 mechanism differentiates it from other investigational agents targeting pathways like myostatin.